

## Leucine Rich Bio provides gut microbiome test to aid stem cell transplantation patients

13 April 2021 | News

**The role and impact of the gut microbiota in intestinal and hematopoietic stem cells have recently been shown in various research studies**



Bengaluru based Leucine Rich Bio, South Asia's first microbiome company, has entered into a collaborative agreement with Dr B. S. Rajput led Scigenomics Pvt Ltd., based in Mumbai, to provide its gut microbiome test, BugSpeaks to patients undergoing stem cell transplantation and the anti-aging treatments.

Gut microbiome dysbiosis is implicated in many diseases like IBD, IBS, type2 diabetes, obesity etc. The role and impact of the gut microbiota in intestinal and hematopoietic stem cells have recently been shown in various research studies. Inflammatory disease like Osteoarthritis and Rheumatoid arthritis have also been shown to have links with the gut microbiota.

Talking about the collaboration Dr Debojyoti Dhar, Co-founder and director, Leucine Rich Bio opines "The impact of the gut microbiota is now being seen in practically all diseases especially immune and inflammation-based ones. A dysbiotic gut can negatively impact lot of organs and in this context, BugSpeaks will be really a good supplementary support for patients who are undergoing stem cell therapy as this will not only provide a snapshot of the intestinal dysbiosis, if any, but will also provide actionable recommendation like personalized nutrition and supplements to take care of it. Taken together, a healthy gut may improve the efficacy and overall quality of life of the patients undergoing stem cell transplantation".

Dr Rajput says, "A combination of high-tech investigations like Bugspeaks and personalized cellular therapies can give

miraculous results in no option diseases like Amyotrophic lateral sclerosis, Rheumatoid Arthritis and interstitial lung disease." He further says that with the establishment of Gut-Lung axis , the microbiome investigation can help a lot of COVID patients, where post COVID syndrome is posing a big problem.

Dr Rajput also emphasizes that Anti-aging is currently the subject of attention globally where aim is prevention of diseases with disease free longer life. In such cases Bugspeaks would be part of all assessment protocols and cell therapy would be of treatment protocols.